DEF: Anteris Technologies Global Corp. Sets 2025 Annual Meeting Agenda

Anteris Technologies Global Corp. announces its 2025 Annual Meeting of Stockholders to address director elections, auditor ratification, and significant RSU grants for executives and non-employee directors.

Summary

• The 2025 Annual Meeting of Stockholders will be held on December 3, 2025, at 5:00 p.m. Central time (December 4, 2025, 9:00 a.m. AEST) in Brisbane, Australia, and via live webcast.
• Stockholders will vote on the election of John Seaberg and Gregory Moss as Class I directors, each to serve until the 2028 annual meeting.
• The appointment of KPMG as the independent registered public accounting firm for the 2025 fiscal year is up for ratification.
• Approval is sought for the grant of 1,000,000 restricted stock units (RSUs) to CEO Wayne Paterson in connection with the U.S. initial public offering (IPO).
• Initial RSU grants to non-employee directors John Seaberg (83,333 RSUs), Stephen Denaro (41,666 RSUs), Gregory Moss (52,742 RSUs), and David Roberts (52,742 RSUs) related to the IPO or Board appointment require approval.
• Annual RSU grants for the 2025 fiscal year to non-employee directors John Seaberg ($250,000 grant date value), Stephen Denaro ($125,000 grant date value), Gregory Moss ($61,644 grant date value), and David Roberts ($61,644 grant date value) are also subject to approval.
• Stockholders will vote on adjustments to the exercise price of certain stock options previously granted under the Employee Incentive Plan to ensure compliance with Section 409A.
• Amendments to the terms of stock options under the 2017 and 2020 Incentive Plans to permit net exercise and net share withholding features require stockholder approval.
• Prior to the U.S. IPO, the company completed a reorganization where Anteris Technologies Pty Ltd (ATPL) became a wholly-owned subsidiary.
• As of October 15, 2025, 36,062,370 shares of Common Stock were outstanding.

Sentiment

Score: 7

Explanation: The filing is a standard proxy statement outlining routine annual meeting proposals, including director elections and auditor ratification. Positively, it details the recent U.S. IPO and corporate reorganization, indicating strategic growth and market access. The extensive equity compensation plans aim to align management and director incentives with shareholder value creation. The company also highlights a comprehensive cybersecurity risk management program. The only minor negative is the need for stockholder approval to correct an inadvertent error in stock option exercise prices for some employees, which is a procedural rather than a fundamental business issue. The ongoing development of the v2vmedtech heart valve repair device, while still in early stages, represents a significant future opportunity.

Positives

• The Board of Directors unanimously recommends 'FOR' all proposals, indicating strong internal alignment and confidence in the proposed actions.
• The company successfully completed a U.S. IPO and corporate reorganization, expanding its market presence and access to capital.
• Equity incentive plans, including significant RSU grants for executives and directors, are designed to align management and director interests with stockholder value creation.
• Robust corporate governance practices are in place, including a classified Board, independent directors, and well-defined committee structures (Audit and Risk, Compensation, Nominating and Corporate Governance).
• A comprehensive cybersecurity risk management program is detailed, including periodic risk assessments, third-party monitoring, and employee training, to protect critical systems and information.

Negatives

• An inadvertent error in setting the exercise prices of certain stock options below fair market value for employees requires stockholder approval for an upward adjustment to comply with Section 409A.
• CDI holders have limited voting and questioning rights during the Annual Meeting, being able to attend virtually only as guests and requiring advance voting instructions.
• The v2vmedtech entity, in which the company holds a 30% stake and provides development services, is a development company with no current revenue generation.

Risks

• Forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results, performance, or achievements to differ materially from expectations.
• Cybersecurity risks, including computer viruses, denial-of-service attacks, phishing, ransomware, unauthorized access, and insider threats, could materially disrupt operations and harm the business.
• The timing for a first-in-human trial for the v2vmedtech heart valve repair device cannot be reasonably determined and is contingent on successful completion of further R&D stages, preclinical testing, and regulatory submissions.
• The v2v Agreements for the development of the heart valve repair device can be terminated if certain expenditure amounts, development milestones, or regulatory approvals are not incurred or achieved from March 31, 2027, onwards.

Future Outlook

The company expects to continue its development of the transcatheter aortic valve replacement program, including the early feasibility study, and aims to drive increased stockholder returns through aligned corporate and individual performance targets. The Equity Plan is designed to provide incentives for service and performance, with automatic increases in the share limit for awards over ten years, reflecting a long-term growth strategy.

Management Comments

• Our Board believes sound corporate governance processes and practices, as well as high ethical standards, are critical to handling challenges and to achieving business success.
• The Compensation Committee believes the setting of key corporate and individual key performance targets which are aligned to the corporate strategy, will drive the development, performance and position of our company.
• The Compensation Committee expects that this will drive increased stockholder returns going forward.
• We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition.

Industry Context

The company operates in the medical technology sector, with a specific focus on developing innovative heart valve repair devices, particularly for transcatheter edge-to-edge repair of mitral and tricuspid valve regurgitation. The recent U.S. IPO and corporate reorganization indicate a strategic move to enhance market access and secure capital for advanced research and development in this specialized and high-growth area of minimally invasive cardiac interventions. The ongoing development of the TEER Product through its v2vmedtech subsidiary positions the company to potentially address significant unmet medical needs within the global cardiovascular device market.

Comparison to Industry Standards

• The company's cybersecurity risk management program, which includes periodic risk assessments, annual security assessments, a third-party Security Operations Center (SOC) partner, external service providers, cyber risk management for vendors, cybersecurity awareness training, disaster recovery plans, and access control systems, aligns with standard best practices for companies operating with critical IT infrastructure and sensitive data in the medical technology industry.
• The executive and director compensation structure, comprising base salaries, short-term incentive bonuses, and long-term equity awards (RSUs and options), is consistent with typical remuneration models in publicly traded companies, designed to attract and retain talent while aligning their interests with shareholder value.
• The requirement for stockholder approval for RSU grants to directors and executives, as well as for adjustments to option terms, demonstrates compliance with ASX Listing Rules (10.14, 6.23.4), which are specific regulatory standards for companies with dual listings or significant Australian operations.

Management Changes

Corporate Governance

Related Party Transactions

• Reorganization Transactions: Prior to the IPO, the company completed a reorganization where Anteris Technologies Pty Ltd (ATPL) became a wholly-owned subsidiary, and ATPL shareholders became holders of the company's Common Stock or CDIs.
• Deed of Cross Guarantee: The company and ATPL are parties to a deed dated December 20, 2024, where they have guaranteed the debts of each other.
• Acquisition of 30% Stake in v2vmedtech, inc.: On April 18, 2023, the company purchased 30% of v2vmedtech's equity, contributed $0.2 million, and entered into development agreements to provide various services for the development of heart valve repair devices. The company's ownership stake will increase to between 58% and 60% after the earlier of Stage 5 completion or $10.0 million in contributions.

Stakeholder Impact

• Shareholders: Will directly influence corporate governance and compensation decisions through their votes at the Annual Meeting. The IPO and reorganization are intended to enhance shareholder value.
• CDI Holders: Have limited voting and questioning rights at the Annual Meeting, requiring them to vote in advance through CHESS Depositary Nominees Pty Ltd (CDN).
• Employees: Benefit from equity incentive plans designed to align their performance with company success, although some are affected by proposed adjustments to stock option exercise prices.
• Directors and Executive Officers: Their compensation packages, including significant RSU grants, are tied to company performance, fostering alignment with stockholder interests. Their roles and responsibilities are clearly defined within the corporate governance framework.
• KPMG: Their appointment as the independent registered public accounting firm for fiscal year 2025 is subject to ratification, continuing their role in ensuring financial transparency.
• v2vmedtech: Receives substantial development contributions and operational support from the company for its heart valve repair device, with the potential for increased ownership by the company upon achieving development milestones.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders on December 3, 2025, to vote on the proposed agenda items.
• Issue RSUs to Wayne Paterson and non-employee directors as soon as practicable following the Annual Meeting, if approved by stockholders.
• Adjust the exercise prices of certain stock options under the Employee Incentive Plan, if Proposal Twelve is approved.
• Amend the terms of stock options under the 2017 and 2020 Incentive Plans to allow for net exercise and net share withholding, if Proposal Thirteen is approved.
• Continue the development of the TEER Product through v2vmedtech, progressing through Stages 2-5 (Concept Freeze, non-clinical bench lab testing, pre-clinical acute and chronic studies, and first-in-human study).
• File voting results on a Current Report on Form 8-K with the SEC within four business days after the Annual Meeting.
• Release the voting results from the Annual Meeting by way of an announcement to the ASX as soon as possible after the conclusion of the meeting.
• Stockholders intending to submit proposals for the 2026 Annual Meeting under Rule 14a-8 must do so by July 13, 2026.
• Stockholders intending to present proposals or nominate directors for the 2026 Annual Meeting (not for proxy statement inclusion) must provide notice between August 5, 2026, and September 4, 2026.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting, primarily focused on corporate governance, director elections, auditor ratification, and executive/director compensation. It does not contain new financial results or operational updates that would significantly alter the investment thesis in the short term. The proposals, including substantial RSU grants and adjustments to option terms, are designed to align management and director incentives with long-term shareholder value, which is generally a positive for a growth-oriented company. The ongoing development of the v2vmedtech project is a key long-term driver, but this filing provides no new material updates on its progress or financial impact beyond expected R&D contributions. Given the absence of new material financial or operational news, a 'hold' recommendation is appropriate, maintaining current positions while awaiting further operational and financial disclosures.

Keywords

Anteris Technologies, Proxy Statement, Annual Meeting, Corporate Governance, Restricted Stock Units, Stock Options, IPO, NASDAQ, ASX, Director Election, Auditor Ratification, Executive Compensation, Equity Incentive Plan, Related Party Transactions, Cybersecurity, Medical Technology, Heart Valve Repair